Delcath Systems (DCTH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled virtually for May 15, 2025, at 10:00 a.m. Eastern Time.
Proxy materials, including the Annual Report and Proxy Statement, are available online and by request.
Stockholders can attend, participate, and vote virtually after registering with their control number.
Voting matters and shareholder proposals
Election of two Class I director nominees: Gerard Michel and Gilad Aharon.
Amendment to the 2020 Omnibus Equity Incentive Plan to increase available shares by 2,200,000.
Amendment to the 2021 Employee Stock Purchase Plan to increase available shares by 300,000.
Ratification of CBIZ, Inc. as the independent registered public accounting firm for fiscal year ending December 31, 2025.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Board of directors and corporate governance
Board recommends voting "FOR" all director nominees and all proposals.
Latest events from Delcath Systems
- Record $85.2M revenue, positive net income, and strong 2026 growth outlook.DCTH
Q4 202526 Feb 2026 - Q2 revenue hit $7.8M with 80% margin; net loss widened, but U.S. growth and NTAP boost outlook.DCTH
Q2 20242 Feb 2026 - Q3 revenue hit $11.2M, net income $1.9M, and $25M raised from warrants; all debt eliminated.DCTH
Q3 202415 Jan 2026 - Registration allows up to $150M in securities to fund oncology growth and operations.DCTH
Registration Filing16 Dec 2025 - Board recommends approval of all proposals, including director elections and plan amendments.DCTH
Proxy Filing2 Dec 2025 - FY2024 revenue hit $37.2M, driven by HEPZATO KIT and positive Q4 adjusted EBITDA.DCTH
Q4 20241 Dec 2025 - Q1 2025 saw $19.8M revenue, $1.1M net income, and strong U.S. expansion.DCTH
Q1 202526 Nov 2025 - Q2 2025 revenue hit $24.2M with strong margins, profitability, and clinical expansion.DCTH
Q2 202523 Nov 2025 - Q3 2025 revenue doubled to $20.6M, with strong margins and cash, but lower net income.DCTH
Q3 202513 Nov 2025